Klinefelter syndrome comorbidities linked to increased X chromosome gene dosage and altered protein interactome activity by Belling, Kirstine González-Izarzugaza et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Jul 10, 2018
Klinefelter syndrome comorbidities linked to increased X chromosome gene dosage
and altered protein interactome activity
Belling, Kirstine González-Izarzugaza; Russo, Francesco; Jensen, Anders Boeck; Dalgaard, Marlene
Danner; Westergaard, David; Rajpert-De Meyts, Ewa; Skakkebæk, Niels E.; Juul, Anders Christian;
Brunak, Søren
Published in:
Human Molecular Genetics
Link to article, DOI:
10.1093/hmg/ddx014
Publication date:
2017
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Belling, K. G-I., Russo, F., Jensen, A. B., Dalgaard, M. D., Westergaard, D., Rajpert-De Meyts, E., ... Brunak, S.
(2017). Klinefelter syndrome comorbidities linked to increased X chromosome gene dosage and altered protein
interactome activity. Human Molecular Genetics, 26(7), 1219-1229. DOI: 10.1093/hmg/ddx014
O R I G I N A L A R T I C L E
Klinefelter syndrome comorbidities linked to increased
X chromosome gene dosage and altered protein
interactome activity
Kirstine Belling1,*, Francesco Russo1, Anders B. Jensen1,
Marlene D. Dalgaard2, David Westergaard1, Ewa Rajpert-De Meyts3,4,
Niels E. Skakkebæk3,4, Anders Juul3,4 and Søren Brunak1
1Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of
Copenhagen, Copenhagen, Denmark, 2Center for Biological Sequence Analysis, Department of Systems
Biology, Technical University of Denmark, Lyngby, Denmark, 3Department of Growth and Reproduction,
Rigshospitalet, University of Copenhagen, Copenhagen, Denmark and 4International Research and Research
Training Centre in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet,
University of Copenhagen, Copenhagen, Denmark
*To whom correspondence should be addressed at: Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences,
University of Copenhagen, Blegdamsvej 3B, DK-2200 Copenhagen, Denmark. Tel: þ45 35325000; Fax: þ45 35325001; Email: kirstine.belling@cpr.ku.dk
Abstract
Klinefelter syndrome (KS) (47,XXY) is the most common male sex chromosome aneuploidy. Diagnosis and clinical
supervision remain a challenge due to varying phenotypic presentation and insufficient characterization of the syndrome.
Here we combine health data-driven epidemiology and molecular level systems biology to improve the understanding of KS
and the molecular interplay influencing its comorbidities. In total, 78 overrepresented KS comorbidities were identified using
in- and out-patient registry data from the entire Danish population covering 6.8 million individuals. The comorbidities ex-
tracted included both clinically well-known (e.g. infertility and osteoporosis) and still less established KS comorbidities (e.g.
pituitary gland hypofunction and dental caries). Several systems biology approaches were applied to identify key molecular
players underlying KS comorbidities: Identification of co-expressed modules as well as central hubs and gene dosage per-
turbed protein complexes in a KS comorbidity network build from known disease proteins and their protein–protein inter-
actions. The systems biology approaches together pointed to novel aspects of KS disease phenotypes including perturbed Jak-
STAT pathway, dysregulated genes important for disturbed immune system (IL4), energy balance (POMC and LEP) and
erythropoietin signalling in KS. We present an extended epidemiological study that links KS comorbidities to the molecular
level and identify potential causal players in the disease biology underlying the identified comorbidities.
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Introduction
Klinefelter syndrome (KS) (47,XXY) is the most common male
sex chromosome aneuploidy with a prevalence of approxi-
mately 1 in 650 males. Diagnosis of KS and prevention and
treatment of its comorbidities keep being a challenge. It is esti-
mated that only 25% of KS males are ever diagnosed due to
variable phenotype and possibly insufficient characterisation
of the syndrome. Many KS males are only diagnosed in adult
life due to infertility (1).
The presence of an extra chromosome can cause higher le-
vels of gene expression and gene products in amounts affected
by regulation at different levels, protein degradation and
modification (2). Also the interaction pattern of the proteins
encoded by the additional chromosome can influence the
severity of a trisomy (3). In the case of KS, X chromosome in-
activation (XCI) counterweights the extra dosage from the
many X chromosome genes (n  2000). Still, roughly 15% of X-
linked genes escape XCI including genes in the two pseudoau-
tosomal regions (PARs) (4).
KS males present certain shared phenotypes such as small
testes, tall stature, narrow shoulders, broad hips, sparse body
hair, gynecomastia and decreased verbal intelligence. KS males
also have increased risk of a wide range of additional disorders
compared to the background population, i.e. comorbidities.
Testicular dysfunction is prevalent in KS. It is estimated that KS
causes 1–3% of all male infertility cases (5). In fact, 10% of all
male patients with azoospermia are likely to be caused by KS.
Numerous KS comorbidities are related to hypogonadism:
osteoporosis, cognitive disorders, metabolic syndrome and dia-
betes and cardiac disease. Consequently, KS males are allocated
lifelong testosterone replacement therapy from puberty. Yet,
the therapy does not counteract or prevent all comorbidities. It
is still unclear whether the chromosome abnormality adds an
extra testosterone-independent facet to the complexity of KS
comorbidities (6).
Comorbidities have been of interest for many years in epi-
demiology studies. In recent years, more data-driven
approaches have linked molecular aetiology to observed dis-
ease correlations extracted from electronic patient records.
Studying disease comorbidities using a systems biology ap-
proach potentially enhances the understanding of disease ori-
gin and progression and the longitudinal interplay between
comorbidities (7,8). Genes associated with the same disease
tend to be co-expressed and work together in protein com-
plexes (9–12). Thus, studying co-expressed genes and protein
complexes can give further functional insight into the biolo-
gical transformation between healthy and diseased individ-
uals and potentially further improve disease diagnosis,
treatment and target discovery (13).
Here we present a population-wide study of KS comorbid-
ities extracted from data in the Danish National Patient Registry
(14) collected over a period of 18.5 years. Gene expression data
was generated from KS patients and controls from peripheral
blood and co-expressed modules of high relevance for the KS
phenotype were identified. A KS comorbidity network was built
based on the extracted disease-pair frequencies, known
disease-associated proteins and their protein–protein inter-
actions (PPIs). Disease distances and nodes central for the inter-
play between diseases were subsequently explored in the
network. The various analytical approaches used in this study
point out the same disturbed functionalities and thereby
strengthen their relevance for KS.
Results
Klinefelter syndrome comorbidities
KS comorbidities were systematically extracted from the Danish
National Patient Registry (14) using the International Classification
of Diseases version 10 (ICD-10) level-3 codes checking for co-
occurrence of the KS code Q98 with all other disease codes (see
‘Materials and Methods’ for details). Comorbidities were defined as
diseases significantly diagnosed a minimum of 50% more fre-
quently in men with KS compared to controls, i.e. relative risk
(RR) 1.5. P-values were obtained using the Fisher’s test and
Benjamini-Hochberg correction was applied to obtain a false dis-
covery rate (FDR) of 5% corresponding to P 0.0082. A total of 78
significant KS comorbidities was identified with a minimum of five
KS patients diagnosed (Supplementary Material, Table S1). Figure 1
displays the KS comorbidities by ICD-10 chapters (short abbrevi-
ations for chapter titles in Supplementary Material, Table S2).
Many well-known KS comorbidities were as expected observed in
the patient records including E29 ‘testicular dysfunction’ (RR¼ 101.
88), M81 ‘osteoporosis without pathological fraction’ (RR¼ 12.433),
N62 ‘hypertrophy of the breast’ (RR¼ 8.252), F79 ‘unspecified men-
tal retardation’ (RR¼ 6.907), E14 ‘unspecified diabetes mellitus’
(RR¼ 6.332), Q53 ‘undescended testicle’ (RR¼ 4.227), E66 ‘obesity’
(RR¼ 4.038) and G40 ‘epilepsy’ (RR¼ 3.928) (15–17). Less established
KS comorbidities were also observed e.g. E23 ‘hypofunction and
other disorders of the pituitary gland’ (RR¼ 8.369), K02 ‘dental car-
ies’ (RR¼ 4.816) and K07 ‘dentofacial anomalities [including mal-
occlusion]’ (RR¼ 3.84). All comorbid level-3 codes were checked for
observations representing phenotypes diverging in opposite direc-
tions as level-4 codes. Only one such case was identified: E29 ‘tes-
ticular dysfunction’ (RR¼ 101.88) that includes both E29.0
‘testicular hyperfunction’ and E29.1 ‘testicular hypofunction’ of
which only the latter was found comorbid with KS (RR¼ 117.67).
Differentially expressed genes in peripheral blood
Blood samples from eight KS patients and eight controls were ex-
pression profiled using microarrays. A total of 12,947 genes were
found to be expressed in at least one of the 16 samples (intensity
cut off 7.27). In this gene set, we found an enrichment of genes
encoded by chromosomes 4 (P¼ 0.0232), X (P¼ 0.017) and Y
(P¼ 2.483e-05) (Fisher’s exact test, P 0.05) (Supplementary
Material, Fig. S1). Statistical testing identified 363 differentially ex-
pressed genes (146 up- and 217 down-regulated) considering an
absolute log2 fold change (lfc) 1.5 and a Benjamini–Hochberg-
corrected FDR of 5% corresponding to P 0.0069 (Supplementary
Material, Table S3).
The most significant differentially expressed and upregu-
lated KS gene was the long non-coding RNA X inactive specific
transcript (XIST) (lfc¼ 8.41). A total of 22 X chromosome genes
was deregulated in KS compared to controls: 16 were up-
regulated (AKAP17A, ASMTL, CSF2RA, EIF1AX, EIF2S3, GPR82,
GTPBP6, IL3RA, PLCXD1, PPP2R3B, PRKX, RP11-EPO6O15.3, SEPT6,
SLC25A6, TMSB4X and XIST) and six were down-regulated
(BEND2, BEX1, COX7B, FOXO4, NHS and TFE3). Some of these
genes were expressed from pseudoautosomal region 1 (PAR1):
AKAP17A, ASMTL, CSF2RA, GTPBP6, IL3RA and PLCXD1, but no
differentially expressed genes were observed encoded from
pseudoautosomal region 2. An interesting observation was the
up-regulation of another long non-coding RNA, RP11-706O15.3.
The function of this gene is still unknown, but it is located near
PAR1 at Xp22.33 and, thus, potentially escapes XCI and/or might
be involved in the XCI process itself.
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Gene set enrichment analysis (GSEA) was performed to gain
functional understanding of the deregulated genes (n¼ 363). The
most enriched biological process terms were ‘immune response’
and ‘response to bacterium’ and the most enriched pathways
were ‘Cytokine–cytokine receptor interaction’ and ‘Jak-STAT sig-
nalling pathway’ (full list in Supplementary Material, Table S4).
The ‘Cytokine–cytokine receptor interaction’ pathway included
18 deregulated genes (seven up-regulated: CCR7, CSF2RA, IFNA4,
IL3RA, IL6ST, IL7R and TNFRSF25; and 11 down-regulated: CXCL1,
CXCL16, CXCL2, CXCR1, EPOR, IL1R1, IL4, INHBB, LEP, LEPR and
OSM). Multiple genes are involved in both the ‘Cytokine–cytokine
receptor interaction’ and the ‘Jak-STAT signalling pathway’
(CSF2RA, EPOR, IFNA4, IL3RA, IL4, IL6ST, IL7R, LEP, LEPR and OSM).
Co-expressed gene modules correlating with Klinefelter
syndrome status
A total of 54 co-expressed modules containing genes with simi-
lar expression patterns was identified by applying weighted
gene co-expression network analysis (WGCNA) (18) (see
Figure 1. Klinefelter syndrome (KS) comorbidities extracted from Danish patient records (n¼78). Comorbidities are summarised by disease chapter and each dot repre-
sents a KS comorbidity with a certain relative risk (RR). The disease chapter titles are shortened (see Supplementary Material, Table S2). There were no comorbidities
between KS and disorders from chapters 2, 7, 8, 16 and 18–21. See Supplementary Material, Table S1 for the full list of KS comorbidities and RRs.
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Figure 2. Gene co-expression modules correlating with Klinefelter syndrome (KS) status. (A) Gene co-expression analysis dendrogram showing co-expressed gene mo-
dules identified using Weighted gene co-expression network analysis (WGCNA) (n¼54). The top colour bar states expression correlation with KS status (red: positive
correlation; blue: negative correlation). The bar below informs about module membership. In total, 27 modules correlated significantly with KS status and reported
here as coloured across the dendrogram. (B) Scaled expression per individual of the 99 genes in the most positively correlated module with KS status, M1/saddlebrown.
(C) Scaled expression per individual of the 81 genes in the most negatively correlated module with KS status, M2/skyblue3.
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‘Materials and Methods’ for details). Of these, 27 modules had
expression signatures that correlated with KS status either posi-
tively (higher expressed in KS than controls, n¼ 14) or nega-
tively (lower expressed in KS than controls, n¼ 13). All modules
were assigned a colour and labelled numerically according to
their degree of significant correlation to KS status (Fig. 2A and
Supplementary Material, Table S5).
The most significant and positively correlated module
was M1/saddlebrown (WGCNA student asymptotic t-test
P¼ 1.12e07) (Fig. 2B). This module included 99 genes including
many X-linked and PAR1 genes: AKAP17A, CA5B, EIF1AX, IL3RA,
SCML1, SEPT6, XIST and ZBED1. An interesting gene in the mo-
dule was DDX17 that recently was discovered as protein interac-
tor of XIST (19). M1 contained 32 of the significantly up-
regulated genes in KS identified in the statistical test described
previously (Supplementary Material, Table S3). GSEA showed
that the M1 genes were involved in the KEGG pathways
‘neuroactive ligand-receptor interaction pathway’ and ‘calcium
signalling pathway’, and several Online Mendelian Inheritance
in Man (OMIM) diseases such as ‘abnormal thyroid hormone
metabolism’, ‘epilepsy’ and ‘deafness’ (Supplementary Material,
Table S5 for complete list).
The most significant negatively correlated module was M2/
skyblue3 (WGCNA student asymptotic t-test P¼ 5.21e06) (Fig.
2C). This module included 81 genes; none of them located in the
PARs. M2 contained 38 of the down-regulated genes in KS and
GSEA revealed enriched biological processes such as ‘immune
system process’ and ‘response to bacteria’ and the KEGG path-
way ‘platelet activation’ (Supplementary Material, Table S5).
Interestingly, both WGCNA and the differential expression ana-
lysis showed significantly enriched biological terms related to
the immune system. These terms contained mainly downregu-
lated genes. In order to evaluate the overlap between the genes
involved in these terms within M2 and the deregulated genes
we computed the hypergeometric distribution obtaining a sig-
nificant overlap (P¼ 3.35e47). This result showed that the
GSEA analysis and the consequent interpretation of the results
were consistent, that is, the down-regulation of genes involved
in the immune system could explain some diseases associated
with KS and its comorbidities.
Supplementary Material, Figure S2 displays the chromosomal
distribution of genes in each of the 27 modules correlating signifi-
cantly with KS status. M1 was one of the modules with the high-
est X chromosome gene content. Yet, overall the modules
contained genes spread out genome-wide underlining that hav-
ing an extra chromosome changes gene expression globally.
Klinefelter syndrome comorbidity network
One of the main aims of this study was to investigate the molecu-
lar relationship between KS and its comorbidities and to identify
key players in their crosstalk. For this purpose, a KS comorbidity
network was constructed consisting of disease sub-networks
each covering KS or one of its comorbidities. Each disease sub-
network was built of associated proteins extracted from disease-
gene databases and following connecting with observed PPIs
from InWeb_InBioMap (InWeb_IM) (11). The disease sub-
networks were following merged into the KS comorbidity net-
work (see ‘Materials and Methods’ and Supplementary Material,
Fig. S3 for further details). Each of the sub-networks were tested
for increased PPI connectivity compared to random networks of
the same size and node degree distribution, thereby testing their
functional relevance under the hypothesis that functionally
related proteins are more likely to interact than unrelated pro-
teins (20). It was possible to build disease sub-networks for KS
and 29 of its comorbidities, and the sub-networks for KS and 22
comorbidity subsequently showed significantly high connectivity
(P-value cut off 0.05) (Supplementary Material, Table S6).
Accordingly, the KS comorbidity network covered 23 diseases
and consisted of 299 nodes and 528 edges (Fig. 3A).
Network distances between each of the disease pairs in the
KS comorbidity network were determined by comparing the
network-based distances between the proteins involved in the
two diseases (21). As expected, most diseases had a negative dis-
ease separation indicating overlapping network topology. The
comorbidities with most PPI topological overlap (TO) to KS was
Q53 ‘undescended testicle’, N46 ‘male infertility’ and E14 ‘un-
specified diabetes mellitus’ (Fig. 3B and Supplementary Material,
Table S7). The comorbidity network had the common topological
characteristics of networks from the molecular level biological
domain and the KS sub-network did not stand out in any topo-
logical measures (see Supplementary Material, Text S1 and Text
S2 for more details and Supplementary Material, Table S8).
Numerous nodes in the network were associated to multiple
KS comorbidities. In this study, we defined two categories of such
nodes: comorbidity nodes and comorbidity-linking hubs. Comorbidity
nodes are associated in disease-gene databases to numerous
comorbidities themselves. Comorbidity-linking hubs are central
to multiple comorbidities through their first-order interaction
partners, which are associated with multiple comorbidities.
Thus, the term ‘hub’ here refers to the centrality of the node to
numerous diseases and is not referring to the PPI connectivity of
the node. The KS comorbidity network can be considered as the
‘backbone’ for tissue-agnostic network and applying gene expres-
sion data from different tissues will give tissue-specific informa-
tion. In this study, we applied the gene expression data from
blood presented above. This data set covered 174 nodes in the
network (Supplementary Material, Table S9).
Some comorbidity nodes were associated with numerous codes
from the same or disease-related ICD-10 chapters, e.g. chapters I
and Q both featuring heart diseases. Of more interest were
comorbidity nodes linking diseases affecting diverse pathophysi-
ology across tissues. Numerous such nodes were present in the
network and involved in up to twelve diseases. Three nodes link-
ing minimum five diseases were significantly down-regulated in
KS: POMC (lfc ¼ 0.762), LEP (lfc ¼ 0.785) and IL4 (lfc ¼ 0.814)
linking seven, six and five diseases, respectively.
Comorbidity-linking hubs were also abundant in the network,
i.e. nodes that connect multiple comorbidities through their
first order interactions partners. The biggest deregulated
comorbidity-linking hubs were: LEP, LEPR (lfc ¼ 0.600), POMC,
EPOR (lfc ¼ 0.603), CSF2RA (lfc¼ 0.648), and IL4 connecting
nine, eight, eight, seven, seven and six diseases, respectively.
Thus, LEP, POMC and IL4 were both comorbidity nodes and
comorbidity-linking hubs, i.e. both associated to multiple di-
seases themselves and also linking multiple diseases through
their first-order interaction partners.
Protein complexes with perturbed functionality in KS
Protein complexes, i.e. clusters, were identified in the comorbi-
dity network. In total 18 significant clusters (P 0.05) were iden-
tified with the most significant cluster, C1, containing 16
proteins: CCR2, CSF2RA, EPO, EPOR, GHR, IL2, IL23R, IL2RA, IL4R,
IL5, IL5RA, IL10RA, JAK2, LEPR, MPL and PKD1 (Fig. 3C and
Supplementary Material, Table S10). These proteins are
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Figure 3. Klinefelter syndrome (KS) comorbidity network, disease separation and protein complex with disturbed functionality. (A) The global KS comorbidity network
created from disease-associated proteins from knowledge databases linked by observed protein–protein interactions (PPIs). The network represents the sub-networks
for KS and the 22 comorbidities with significant high connectivity. Nodes are coloured according to their associated disease chapter similarly to Figure 1. Nodes associ-
ated to diseases belonging to multiple chapters are multi-coloured. Node size is scaled to the number of KS comorbidities each node is associated with. (B) Disease se-
parations of the 23 diseases represented in the comorbidity network clustered after similarity and only including edges between diseases with overlapping network
topology. (C) The most statistical significant cluster in the network. The size and colouring of the nodes are similar to in the full network. Node border colour represents
significant up- (red) and down-regulation (blue) in KS compared to controls.
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involved in three main KEGG pathways: ‘Cytokine–cytokine re-
ceptor interaction’, ‘Jak-STAT signalling pathway’ and ‘hemato-
poietic cell lineage’ and also related to numerous KS
comorbidities such as obesity, diabetes mellitus, atherosclerosis
and respiratory disorders. In this cluster, CSF2RA, LEP and EPOR
were deregulated as before mentioned, which might cause this
complex to have disturbed functionality in KS.
Discussion
KS is the most common male sex chromosome aneuploidy. KS
males have a 70% increased risk of being hospitalized and have a
reduced life expectancy by two years compared to normal karyo-
type males due to increased disease susceptibility (22). Still, KS is
under diagnosed and treatment is most often limited to testoster-
one therapy, which overcomes some but by far all comorbidities.
In this study, we identified 78 significant KS comorbidities using
population-wide patient record data. Up to half of the diseases
were not previously reported in comorbidity studies on KS comor-
bidities (15–17). Among the novel and unexpected comorbidity
findings was E23 ‘hypofunction and other disorders of the pituit-
ary gland’ (RR¼ 5.42). Usually KS males present a normal growth
hormone-IGF-I axis (23) and increased luteinizing hormone and
follicle-stimulating hormone levels due to their androgen defi-
ciency (17,24). Our observation could in theory result from in-
appropriate ICD-10 registration of luteinizing hormone/follicle-
stimulating hormone hyposecretion observed during androgen re-
placement therapy, which occasionally suppresses gonadotropins
to subnormal levels due to negative feedback. Another still less es-
tablished comorbidity of KS is dental anomalies although several
case studies of observed late eruption and dental problems in KS
males have been published (25–28). Consequently, a conclusion
from this study is to prioritise dental observation of KS males.
XCI compensates extensively for the extra X chromosome
gene dosage in KS males and probably increases their chances
of survival compared to other aneuploidies. The master effector
of XCI, the non-coding RNA XIST, was the most significantly
upregulated gene in KS consistent with previous findings
(29,30). Still, it is estimated that approximately 15% of the X
encoded genes escape XCI (31) prompting the characteristic KS
phenotypes and comorbidities. In this study, we identified the
genes escaping XCI. We found that the majority of the 363 sig-
nificantly deregulated genes were not X encoded. Thus, having
an extra X chromosome influences gene expression across the
genome and underlines the trans-regulatory effect of the es-
capees. Interestingly, it has been shown that the mere presence
of extra chromosome leads to genomic instability and changes
in gene expression in cancer cell lines (32–34). These studies
showed that gain of chromosomes triggers replication stress
promoting genomic instability and possibly contributing to
tumorigenesis in cell lines. Moreover, the authors showed a re-
markable change in the transcriptional regulation (33). Other
studies showed that excess expression of one or more X
chromosome genes influences brain development and it has
been hypothesized that specific brain-expressed genes that are
known to escape XCI could be responsible for cognitive dis-
orders of KS patients (35,36). Future work with in vivo analyses is
needed to better understand this phenomenon, but the gain of
extra chromosomes seems to be responsible for the observed
changes in the global gene expression.
The most enriched biological process term for the 363 diffe-
rential expressed genes was ‘immune response’. This is consistent
with that the lack of testosterone in KS patients enhances cellular
and humoral immunity and androgen replacement treatment
may suppress this process (37). Moreover, it has been reported that
infectious diseases cause increased mortality of KS patients (38).
Previously focus has mostly been on single protein–disease
relationships. Yet, proteins work in concert and we are only start-
ing to fully understand how protein subunits work in a network
perspective. The KS comorbidity network emphasises knowledge
that can be further studied as disease interplay at the PPI level.
The three downregulated comorbidity nodes and comorbidity-
linking hubs, POMC, LEP and IL4, are involved in the regulation of
energy balance and the immune system, both known to be af-
fected by KS. POMC is a hormone precursor for multiple peptides
active across tissues including adrenocorticotropic hormone that
regulates cortisol release, and also the three melanocyte stimu-
lating hormones that balance food intake and energy consump-
tion amongst others. LEP is also a long-term regulator of the
energy balance by suppressing food intake and works through
POMC-containing neurons (39). IL4 is produced by T-cells and
plays an essential role in inducing adaptive immune response
(40). Possibly, IL4 also plays a role in autoimmune diseases, which
KS patients have increased risk of, including triggering self-
antigen presentation in pancreatic islet cells driving the develop-
ment of autoimmune diabetes (41). The comorbidity-linking hub
EPOR is the receptor for EPO. Testosterone stimulates erythropoi-
esis through EPO stimulation (42). Thus, the observed hypoandro-
genism in KS might explain the down-regulation of EPOR.
The combined network biology approaches used in this study
emphasised perturbation of ‘cytokine–cytokine receptor inter-
action’ and ‘Jak-STAT pathways’, immune system alterations
and disturbed EPO signalling and energy balance through POMC
and LEP in KS. LEP and EPO appear relevant to the increased
prevalence of at least diabetes and obesity in KS patients (43) and
might be used as biomarkers for the clinical management of KS
in the future. An interesting observation was that both LEP and
LEPR were down-regulated. Another possible future treatment of
KS might be to add additional XIST molecules edited to comple-
ment the escapees like it was done recently for Trisomy 21 (44).
This could lead to silencing of the complete extra X chromosome.
Administering such treatment in foetal life has the potential of
KS males being symptom free, because it obstructs the primary
inducers of the KS-associated comorbidities.
A potential weakness of this study is that the use of registry
data solely consisting of hospital diagnosis data for each pa-
tient. There are several factors such as socio-economic factors,
lifestyle and other drug prescriptions that affect the risk of di-
seases. However, it is difficult to obtain such data for the entire
population of a full country. Thorough follow-up studies should
include as many as these as possible.
As already mentioned a significant fraction of KS patients
are never diagnosed. The comorbidity profile of KS described in
this study could potentially be used to identify undiagnosed pa-
tients. However, the use of a disease trajectory approach similar
to the one published earlier (45,46) where the temporal order of
diseases is incorporated would presumably be more powerful
compared to the comorbidity profile described here. This will be
the target of further work.
Although the expression data from different individuals in
general was in good agreement the cohort is admittedly small.
Nevertheless, we pointed out the importance and power of data
integration approaches, in particular the integration of comor-
bidities with other biological data types. In future studies we
will increase the number of samples, in order to further confirm
the results. In this work, a first attempt has been done providing
relevant results consistent with previous studies and adding
novel biological aspects of KS.
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In this study, several novel and less clinically established KS
comorbidities were identified in an unbiased, data-driven way.
Several genes in the identified co-expressed modules, network
hubs and clusters may be promising biomarkers for prevention
or treatment of common KS comorbidities. The data-driven epi-
demiological approach presented here can be applied to any an-
euploidy and disease in general and shed light on their dosage-
provoked comorbidities, established as well as non-established
ones pointing at their aetiology and molecular interplay.
Materials and Methods
Klinefelter syndrome comorbidities
Comorbidities were identified from the over-occurrence of KS
with another disease, X, compared to individuals not having KS.
In this study, we used diagnoses from electronic patient records
in the Danish National Patient Registry (14) for 6.8 million pa-
tients hospitalized between 1996 and 2014 comprising 90 mil-
lion hospital encounters and 87 million unique patient-
diagnosis associations at the ICD-10 level-3 (45,47).
ICD-10 has a hierarchical structure divided into chapters,
blocks, level-3 codes and finally level-4 codes, which are the
most specific. Each level-4 code can be ‘rounded’ to its parent
level-3 code and further to the block or chapter. To get larger
counts and thereby better statistics, we have used level-3 codes.
This also reduces a misclassification where an inappropriate
level-4 code was selected among the level-4 codes under a spe-
cific level-3 code.
KS comorbidities were extracted using the level-3 disease
code Q98 ‘other sex chromosome abnormalities, male pheno-
type, not elsewhere classified’, but only including patients diag-
nosed with level-4 codes Q98.0 ‘KS karyotype 47,XXY’, Q98.1 ‘KS,
male with more than two X chromosomes’, Q98.2 ‘KS, male
with 46,XX karyotype’ or Q98.4 ‘KS, unspecified’ (n¼ 595).
Comorbidities were defined as significantly increased RR of Q98
co-occurring with other level-3 ICD-10 codes when compared to
a control population. Fisher’s Exact test was used to assign a P-
value to the association using uncorrected counts. We defined
the full control population as all patients in the Danish National
Patient Registry without a KS diagnosis. Including all patients
from this population as the non-exposed comparison group in
the statistical analysis will give a very skewed number of
exposed (KS) patients versus non-exposed patients. Therefore,
we sampled a matched background (BG) population including
20 controls per KS patient. The choice of 20 control patients per
KS patient is a compromise between having enough controls to
pick up rare diseases, but not too many to increase the statis-
tical power of the test. The controls were matched to have same
gender and year of birth as the KS patient.
RR is normally defined as:
RR¼ ðKS w: disease XÞ=ððKS w: disease XÞþðKS wo: disease XÞÞðBG w: disease XÞ=ð BG w: disease Xð ÞþðBG wo: disease XÞÞ
With this definition, RR overestimates the association of rare
diseases. This can be addressed by adding, a pseudo count (or
continuity correction) to each of the four patient groups in the
calculation of the RR. For a pseudo count of k, RR is defined as:
RR ¼ ðKS w: disease Xþ kÞ=ððKS w: disease Xþ kÞ þ ðKS wo: disease Xþ kÞÞðBG w: disease Xþ kÞ=ð BG w: disease Xþ kð Þ þ ðBG wo: disease Xþ kÞÞ
A study found a pseudo count of 1/2 to be recommended for
a generalization of Fisher’s Exact test to N groups (the Mantel–
Haenszel procedure) (48). We rounded this to an integer of 1. For
the comorbidities, we required a minimum of five KS patients
diagnosed with disease X and a RR 1.5. We utilized Benjamini–
Hochberg to limit the FDR to 5%. The level-4 ICD-10 subcatego-
ries of the extracted KS comorbidities were checked for observa-
tions representing phenotypes diverging in opposite directions.
Three level-3 codes had phenotypic opposite directed level-4
codes: E23 ‘Hypofunction and other disorders of pituitary gland’,
E29 ‘Testicular dysfunction’ and E34 ‘Other endocrine dis-
orders’. For these three level-3 codes, we used the level-4 codes
to get more detailed information after seeing that the level-3
code was significant.
Gene expression data and analysis
Blood samples were available from eight KS males and eight
normal karyotype male controls. Total RNA was extracted with
QIAamp RNA Blood Mini Kit (QIAGEN, Hilden, Germany) accor-
ding to the manufacturer’s protocol. RNA quantity and quality
was determined using NanoDrop (Thermo Scientific,
Wilmington, Delaware, US) with Bioanalyzer Nano Kit (Agilent
Technologies, Santa Clara, California, US). The samples were
amplified (one round) using the MessageAmp II aRNA
Amplification Kit (Applied Biosystems, Carlsbad, California, US)
and the aRNA was applied and run on Agilent Human Genome
Microarrays 44K (Agilent Technologies, Santa Clara, California,
US). Hybridization and scanning of the one-color arrays were
performed according to instructions from the manufacturer
(Agilent Technologies, Santa Clara, California, US).
Processing of the gene expression microarray data was per-
formed using the R software suite version 3.3.1 (www.r-project.
org). gProcessedSignals were loaded into the limma R/
Bioconductor package (49,50) and normalized between arrays
using the quantile normalization procedure (51). Probes were
collapsed for each systematic gene ID by taken the median ex-
pression value. The age of the KS patients and controls varied
(Supplementary Material, Table S11), which was corrected for
using the ComBat method (52) implemented in the Surrogate
Variable Analysis package (53). A Gaussian mixture model was
employed to determine a threshold of genuine gene expression
using the mixtools package (54). The expectation maximization
algorithm was used to model the log2-transformed intensity sig-
nals of the probes using a mixture of three Gaussian distribu-
tions. Genes with mean of log2-transformed expression values
over the 95% percentile of two distributions of lowest expressed
genes were considered expressed (cut off 7.27) and included in
the further analysis. The expectation maximization algorithm
was implemented using the normalmixEM function from the
mixtools R package. The limma package (50) was used to per-
form differential expression analysis. Genes were considered
differentially expressed if having an absolute fold change 1.5
and an Benjamini–Hochberg-corrected P 0.05. The raw micro-
array data is deposited in ArrayExpress with accession number
E-MTAB-4922. Description of the arrays are available in
Supplementary Material, Table S11.
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Co-expressed gene modules correlating with KS status
The WGCNA package in R was used to define co-expressed gene
modules (55). Correlations were estimated using the biweight
mid-correlation and a signed weighted correlation network was
used to identify co-expression modules with high TO (18). The
TO is a useful approach to exclude spurious or isolated connec-
tions during network construction. TO considers each pair of
genes in relation to all other genes in the network. Genes have
high TO if they are connected to roughly the same group of
genes in the network (i.e. they share the same neighbourhood).
The TO captures relationships among neighbourhoods of genes,
and is therefore more robust than pairwise correlation alone for
clustering genes by similarity (18).
Modules were defined as branches of a hierarchical cluster
tree using the top-down dynamic tree cut method (56). The ex-
pression patterns of each module were summarized by the
module eigengene, defined as the first principal component of a
given module. Pairs of modules with high module eigengene
correlations (r> 0.9) were merged. A weighted signed network
was computed based on a fit to scale-free topology. A threshol-
ding power of 26 was chosen (lowest threshold resulting in a
scale-free R2 fit of 0.8), and the pairwise TO between genes was
calculated, which converted pairwise correlation values [1,1]
to TO co-expression values [0,1] where values close to 1 repre-
sented highly shared co-expression neighbourhoods. The TO
dendrogram was used to define modules using the dynamic
tree cut method function in WGCNA (55) with a minimum mo-
dule size set to 40 genes and the deepSplit parameter set to 2
(57). Finally, a measure of module-disease and gene-disease cor-
relations to KS were calculated, Student asymptotic P-value,
using the R function corPvalueStudent of the WGCNA method.
The gProfileR package (58) was used to compute the GSEA of
the differentially expressed genes and the genes in modules.
The background was set to the total list of expressed genes
defined above. The hypergeometric distribution was used to es-
timate the significance of enriched pathways and processes
using a threshold of FDR 5%.
Klinefelter syndrome comorbidity associated proteins
and network
In order to identify proteins associated with KS comorbidities
we created a mapping between the Disease Ontology Database
(59) and ICD-10 codes, and then used the associations between
diseases and proteins extracted from the Diseases database
(60), Genetics home reference (61), OMIM (62) and the UniProt
Knowledgebase (63). Disease sub-networks were built for KS
and all extracted comorbidities with associated proteins con-
nected with observed physical PPIs. We used high confidence
PPIs from InWeb_IM (11) using the recommended cut off of con-
fidence score 0.1. A common hypothesis is that proteins asso-
ciated to the same disease and, thus, having some functional
relationship, are more likely to interact than randomly selected
proteins (20). Therefore, each disease sub-network was statistic-
ally tested for this hypothesis by comparing the observed num-
ber of PPIs between the disease proteins compared to 1,000
random sub-networks of the same size and node degree distri-
bution picked randomly in the whole InWeb_IM network of high
confidence interactions. P-values were calculated as the propor-
tion of random networks with equal or more PPIs than the true
network (workflow illustrated in Supplementary Material, Fig.
S3). A significance level of P 0.05 was set as cut off for a func-
tional network. Disease separations were calculated as
previously published (21) and network topology was investi-
gated (see Supplementary Material, Text S1). Subsequently, the
ClusterONE algorithm (64) implemented in Cytoscape (65) was
used to extract protein clusters using the default parameters
and the InWeb_IM confidence score as edge weights.
Supplementary Material
Supplementary Material is available at HMG online.
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